Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks.

"Conflicts of interest EtH has carried out investigator-initiated research with financial support from Almirall and has carried out clinical trials for Novartis. All funding is not personal but goes to the independent Research Fund of the Department of Dermatology of Radboud University Medical Centre Nijmegen (Radboudumc), The Netherlands; JvdR carried out clinical trials for AbbVie, Celgene and Janssen and has received speaking fees/attended advisory boards from AbbVie, Janssen, BMS, Almirall, Leo Pharma, Novartis, UCB and Eli Lilly and reimbursement for attending a symposium from Janssen, Pfizer, Celgene and AbbVie. All funding is not personal but goes to the independent research fund of the Department of Dermatology of Radboudumc Nijmegen, the Netherlands; KGdJ and ABC are employers of Almirall; EdJ has received research grants for the independent research fund of the Department of Dermatology of Radboudumc Nijmegen, the Netherlands from AbbVie, BMS, Janssen, Leo Pharma, Novartis, and UCB for research on psoriasis. Has acted as consultant and/or paid speaker for and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis or eczema including AbbVie, Amgen, Almirall, Celgene, Galapagos, Janssen, Lilly, Novartis, Leo Pharma, Sanofi and UCB. All funding is not personal but goes to the independent research fund of the Department of Dermatology of Radboudumc Nijmegen, the Netherlands; SL has received research grants for investigator-initiated research from Almirall and has acted as consultant, advisory board member and/or paid speaker for Leo Pharma, Sanofi Genzyme, Sunpharma, Almirall, and Janssen. All financial compensations/grants were paid to the independent research fund of the Department of Dermatology of Radboudumc Nijmegen, the Netherlands."

"Conflicts of interest: EtH has carried out investigator-initiated research with financial support from Almirall and has carried out clinical trials for Novartis. All funding is not personal but goes to the independent Research Fund of the Department of Dermatology of Radboud University Medical Centre Nijmegen (Radboudumc), The Netherlands; JvdR carried out clinical trials for AbbVie, Celgene and Janssen and has received speaking fees/attended advisory boards from AbbVie, Janssen, BMS, Almirall, Leo Pharma, Novartis, UCB and Eli Lilly and reimbursement for attending a symposium from Janssen, Pfizer, Celgene and AbbVie. All funding is not personal but goes to the independent research fund of the Department of Dermatology of Radboudumc Nijmegen, the Netherlands; KGdJ and ABC are employers of Almirall; EdJ has received research grants for the independent research fund of the Department of Dermatology of Radboudumc Nijmegen, the Netherlands from AbbVie, BMS, Janssen, Leo Pharma, Novartis, and UCB for research on psoriasis. Has acted as consultant and/or paid speaker for and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis or eczema including AbbVie, Amgen, Almirall, Celgene, Galapagos, Janssen, Lilly, Novartis, Leo Pharma, Sanofi and UCB. All funding is not personal but goes to the independent research fund of the Department of Dermatology of Radboudumc Nijmegen, the Netherlands; SL has received research grants for investigator-initiated research from Almirall and has acted as consultant, advisory board member and/or paid speaker for Leo Pharma, Sanofi Genzyme, Sunpharma, Almirall, and Janssen. All financial compensations/grants were paid to the independent research fund of the Department of Dermatology of Radboudumc Nijmegen, the Netherlands."

"This is a post hoc pooled analysis of 2 3-part, randomized, double-blind, placebo-controlled, parallel-group, phase III trials (reSURFACE 1 and reSURFACE 2, ClinicalTrials.gov NCT01722331 and NCT01729754) that evaluated the efficacy and safety of TIL in patients with moderate to severe chronic plaque psoriasis for up to 5 years (, ). reSURFACE 2 included etanercept as an active comparator (). reSURFACE 1 was conducted from 10 December 2012 to 28 October 2015. reSURFACE 2 was conducted from 12 February 2013 to 28 September 2015."